These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.
Please note that the physiological activity of the ingredient(s) described herein is supported by the referenced clinical trial reports. Marketers of finished products containing the ingredient(s) described herein are responsible for determining whether claims made for such products are lawful and in compliance with the laws of the country in which they will market the products.

 

RESEARCH

  • Liu W et al. Development of a neuroprotective potential algorithm for medicinal plants. University of Rhode Island. Neurochem Int. 2016 Sep 29. 100: 164-177. - As part of a strategy to help guide the selection and evaluation of medicinal plant candidates for their neuroprotective potential, researchers at the University of Rhode Island developed a Neuroprotective Potential Algorithm (NPA) by evaluating twenty-three standardized and chemically characterized Ayurvedic medicinal plant extracts in a panel of bioassays targeting oxidative stress, carbonyl stress, protein glycation, amyloid beta (Aβ) fibrillation, acetylcholinesterase (AChE) inhibition, and neuroinflammation. Bacognize showed the highest in anti-Aβ fibrillation in both methods.

  • Kumar et al. Efficacy of standardized extract of Bacopa monnieri (Bacognize) on cognitive  functions of medical students: A six-week, randomized placebo-controlled trial. Evidence-Based Comp Alter Med. 2016 Sep 15. Vol 2016 (Art ID 4103423): 8pgs. doi: 10.1155/2016/4103423 - In a randomized, placebo controlled crossover human clinical trial, administration of Bacognize® at 300mg/day to healthy medical students significantly improved (p<0.05) several parameters of cognitive function, including memory, focus, and attention. No adverse events were reported in either the Bacognize® or placebo groups.

  • Headapohl et al. Effects of Bacopa monnieri (Bacognize®) on memory and cognitive function in healthy older adults: A double-blind placebo-controlled study. Unpublished Manuscript. - In a randomized, placebo controlled trial in older adults, positive trends in working memory, attention, and focus were seen in the Bacognize® group (300mg/day) compared to placebo. Further, no adverse events were reported in either the Bacognize or placebo groups.

  • Hingorani L et al. Sustained cognitive effects and safety of HPLC-standardized Bacopa monnieri  (Bacognize) extract: A randomized, placebo controlled clinical trial. Planta Med. 2012. 78-PH22. Poster. doi: 10.1055/s-0032-1320681 - In a randomized, placebo controlled trial in older adults, significant improvement in the Bacognize® group (300mg/day) was seen over placebo in short-term memory, processing speed, attention, and depression. Additionally, an effect was observed four weeks after administration discontinued. No adverse events were reported in either the Bacognize® or placebo groups.

  • Goswami S et al. Effect of Bacopa monnieri (Bacognize) on cognitive function in patients. Int J Collab Research Internal Med. 2011 May 10. 3(4): 285-293. ISSN: 1840-4529 - Improvement in the Bacognize® group (300mg/day) was seen over placebo in areas of cognitive function in this six-month clinical trial conducted on geriatric AD subjects. No adverse events were reported in either the Bacognize® or placebo groups.

  • Hall et al. Pharmacology of Bacopa monnieri (Bacognize®) at 5HT1a and 5HT2a receptors. Am Soc Pharmacog Absts. 2005. 83-85. Poster Presented at 2005 Annual Mtg Am Soc Pharmacog, Corvallis, OR. - Pharmacology research on Bacognize and its isolated constituents showed strong regulation at serotonin receptors that are key for higher cognitive functions such as memory, mood, and focus.

  • Stough et al. Examining the nootropic effects of a special extract of Bacopa monniera on human cognitive functioning: 90 day double-blind placebo-controlled randomized trial. Phytother Res. 2008 Dec. 22(12): 1629-1634. doi: 10.1002/ptr.2537 - Patients took 300mg of a Bacopa monniera extract per day for 90 days or a placebo and underwent neuropsychological testing. It was shown that the extract significantly improved performance on the working memory factor and also reduced the number of false positives recorded in the Rapid Visual Information processing task.

  • Calabrese C et al. Effects of a standardized Bacopa monnieri extract on cognitive performance, anxiety, and depression in the elderly: A randomized, double-blind, placebo-controlled trial. J Altern Complement Med. 2008 Jul. 14(6): 707-713. doi: 10.1089/acm.2008.0018 - Elderly patients without dementia took a standardized B. monnieri extract 300 mg a day or a placebo for 12 weeks. Results showed that Bacopa participants had enhanced AVLT delayed word recall memory scores compared to placebo, as well as CESD-10 depression scores, combined state plus trait anxiety scores, and heart rate decreasing over time for the Bacopa group, while these measurements increased for the placebo group.

  • Stough et al. The chronic effects of an extract of Bacopa monnieri (Brahmi) on cognitive function in healthy human subjects. Psychopharmacology (Berl). 2001 Aug. 156(4): 481-4. - Patients took 300 mg of  a B. monniera extract everyday for 12 weeks. Results showed that B. monniera significantly improved speed of visual information processing, learning rate, and memory consolidation measured by the AVLT, along with state anxiety being reduced, all compared to placebo. Maximal effects were evident after 12 weeks, which could indicate progressive rather than regressive positive effects over time.

  • Bacopa monnieri: Monograph. Altern Med Rev. 2004 Mar. 9(1): 79-85. Review. - A review over the Bacopa monniera, including a description, active constituents, mechanisms of action, clinical indications, and safety information. The topic mostly discussed is the improvements in cognitive function that the plant provides.